Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN E versus ERYTHROMYCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN E versus ERYTHROMYCIN STEARATE.
E-MYCIN E vs ERYTHROMYCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptides.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
250-500 mg orally every 6 hours or 500-1000 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
1.4-2 hours in adults with normal renal function; prolonged to 5-6 hours in anuria; unchanged in hepatic impairment.
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Primarily excreted in bile as active drug; about 2-5% excreted renally as unchanged drug. Up to 15% excreted in feces.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic